Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Evommune, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
EVMN
New York
2834
www.evommune.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Evommune, Inc.
Evommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights
- Nov 12th, 2026 2:05 pm
Pelthos Therapeutics Inc. (PTHS) Reports Q3 Loss, Lags Revenue Estimates
- Nov 12th, 2026 5:25 am
Evommune to Present at Upcoming Investor Conferences
- Nov 9th, 2026 6:05 am
Evommune Licenses Experimental Arthritis Drug, Raises $30 Million to Fund Development
- Nov 6th, 2026 9:14 pm
Evommune signs $1.1bn licence deal with Hinova for EVO570
- Nov 5th, 2026 4:36 am
Evommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
- Nov 5th, 2026 4:30 am
Evommune Announces $30 Million Private Placement
- Nov 4th, 2026 3:10 pm
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
- Nov 4th, 2026 3:02 pm
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight
- Oct 19th, 2026 11:00 am
EADV26: Key late-stage readouts from the conference
- Oct 5th, 2026 5:57 am
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
- Oct 1st, 2026 6:00 am
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
- Sep 23rd, 2026 2:05 pm
Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline?
- Sep 16th, 2026 1:55 pm
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
- Sep 11th, 2026 3:37 am
Sector Update: Healthcare Stocks Decline in Afternoon Trading
- Sep 9th, 2026 11:34 am
This Biotech Has Lost 50%-Plus On Just One Drug; Why It's Still Trucking On
- Sep 9th, 2026 8:01 am
Evommune Halts Atopic Dermatitis Program Following Trial Failure
- Sep 9th, 2026 5:40 am
Why Is EVMN Stock Down 13% After-Hours?
- Sep 8th, 2026 5:51 pm
Scroll